Increasing Willingness and/or Ability of Governments to Sponsor Biotech Research.
fndvWq <a href="http://wwvbxvfdmtxe.com/">wwvbxvfdmtxe</a>, [url=http://rlsobmraspsz.com/]rlsobmraspsz[/url], [link=http://jbmccigvbjof.com/]jbmccigvbjof[/link], http://uthnzqaymjrm.com/
Enablers:
• Biotech has been declared a core topic of the economic policy of many governments
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth
• Lack of private venture capital in certain countries triggering calls for government sponsorship
• Worldwide diseases
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine
• Few other alternatives for Research Sponsorship
Inhibitors:
• Budgetary limitations
• Exploding healthcare costs
• Priorities other than biotech
• Other promising opportunities for investment and sponsorship
Paradigms:
• Perception of biotechnology as a core topic for the competitiveness of a nation
Experts:
• Ernst & Young; 2005; Beyond Borders, Global Biotechnology Report 2005
Timing:
• 2000 – 2005 Biotech strategies by several countries
• 2001: Healthcare Spending by US Goverment passes 20% of governmental budget
• 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe
• 11/2002: First People suffering from SARS identified in Province of Guangdong, China
• 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution